Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709588 | 1.00 | KMT2A (0.49) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL7301131 | 1.00 | KMT2A (0.49) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL7433845 | 0.89 | KDM4E (0.45) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL11981992 | 0.89 | REN (0.48) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL13840602 | 0.89 | REN (0.48) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL7433838 | 0.89 | KDM4E (0.45) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL10751934 | 0.89 | CTNNB1 (0.47) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL7289410 | 0.89 | CTNNB1 (0.47) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL421814 | 0.88 | REN (0.48) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL13839332 | 0.88 | REN (0.48) | KMT2AMEN1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8378099-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACUETICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-8003791-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-0788360-B3 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7531526-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1997823-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1627880-B1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARM INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-5039664-A | Hypotensive agent | MERCK & CO., INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-5037807-A | Hypotensive agents; for treatment of congestive heart failure | MERCK & CO., INC. (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0427939-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0416393-A1 | Peptidyl difluorodiol renin inhibitors | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0341602-A2 | Renin-inhibiting functionalized peptidyl aminodiols and - triols | ABBOTT LABORATORIES (US) | 1989-11-15 | — | — | EP | disclosed |
| EP-0326364-A2 | Renin inhibitory oligopeptides, their preparation and use | Sankyo Company Limited (JP) | 1989-08-02 | — | — | EP | disclosed |
| US-4839357-A | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE | MERCK & CO., INC. (US) | 1989-06-13 | — | — | US | disclosed |
| US-4826958-A | HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0278158-A2 | Renin inhibitors containing phenylalanyl-histidine replacements | MERCK & CO. INC. (US) | 1988-08-17 | — | — | EP | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | KMT2A 4259/4885MEN1 2373/4885ALDH1A1 3283/4885 |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | KMT2A 4259/4885MEN1 2373/4885ALDH1A1 3283/4885 |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | KMT2A 4259/4885MEN1 2373/4885ALDH1A1 3283/4885 |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | KMT2A 4259/4885MEN1 2373/4885ALDH1A1 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.